Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

876
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
876

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

Leukemia & lymphoma·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Blood·2026
Same author

Olutasidenib as maintenance therapy after treatment response in acute myeloid leukemia with persistent <i>IDH1</i> mutation.

Blood neoplasia·2026
Same author

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.

Blood advances·2026
Same author

Flow cytometric assessment of measurable residual disease in acute myeloid leukaemia: a summary of current Australasian practice and future directions.

Internal medicine journal·2026

相关实验视频

Updated: Jan 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

627

MNT:洗钱防治的新目标

Karla C Fischer1,2, Veronique Litalien1, Sarah T Diepstraten1,2

  • 1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.

Blood neoplasia
|October 27, 2025
PubMed
概括
此摘要是机器生成的。

马克斯网络转录抑制剂 (MNT) 驱动骨髓性白血病. 在小鼠和人类急性髓性白血病 (AML) 中删除MNT诱导癌细胞死亡和改善存活率,这表明MNT抑制剂用于AML治疗.

更多相关视频

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K

相关实验视频

Last Updated: Jan 14, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

627
Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.8K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 血液学 血液学 血液学

背景情况:

  • 放松c-MYC表达是众所周知的各种癌症的驱动因素.
  • 涉及混合血统白血病 (MLL) 融合蛋白的髓性白血病是一个重大的临床挑战.
  • 在MLL驱动的白血病中,MYC家族成员MNT (MAX网络转录抑制剂) 的作用以前未被探索.

研究的目的:

  • 研究MLL驱动的髓性白血病对MNT的依赖.
  • 评估针对MNT在急性髓性白血病 (AML) 的治疗潜力.

主要方法:

  • 使用血造复制模型生成Mnt可删除的小鼠MLL::AF9急性髓性白血病 (AML).
  • 在体外对AML细胞亡的Mnt删除效应的评估,包括对BH3模仿药物的反应.
  • 在体内研究包括在移植的小鼠和人类AML模型 (包括NSG小鼠) 中Mnt删除和在人类AML细胞系中进行CRISPR/Cas9基因编辑.

主要成果:

  • 在MLL::AF9 AML细胞中,Mnt删除在体外诱导了亡,并使它们对BH3模仿药物敏感.
  • 在体内Mnt删除显著延长了MLL:AF9AML小鼠的存活时间,50%的小鼠实现了无白血病状态.
  • 删除MNT增强了BH3模仿药物对人类AML细胞系的疗效,并在体内减少了白血病负担.

结论:

  • 由MLL驱动的髓性白血病依赖于MNT.
  • 删除MNT代表了AML有前途的治疗策略,增强对现有药物的敏感性.
  • 用小分子准MNT功能可能为髓状和淋巴状恶性瘤提供一种新的治疗方法.